• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Senzime

4.37 SEK

-1.02 %

Less than 1K followers

SEZI

NASDAQ Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.02 %
-4.49 %
+0.58 %
-19.17 %
-18.41 %
-14.75 %
+45.50 %
-80.50 %
-26.45 %

Senzime operates in the medical technology industry and focuses on the development and manufacture of systems for monitoring and diagnostics in healthcare. The portfolio includes systems used to automate and measure the substances glucose and lactate in blood and tissues. The company's products are aimed at healthcare institutions and physicians. The operations are global. Senzime was founded in 1999 and is headquartered in Uppsala, Sweden.

Read more
Market cap
686.24M SEK
Turnover
323.06K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
16.7.
2026

Interim report Q2'26

29.10.
2026

Interim report Q3'26

All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release6/5/2026, 8:00 AM

Senzime to Showcase Expanded TetraGraph Capabilities with Launch of TetraAnalytics at Euroanaesthesia 2026

Senzime
Press release6/3/2026, 9:45 AM

Senzime strengthens position in pediatric anesthesia by securing another hospital contract and highlighting positive outcome data

Senzime
Press release6/1/2026, 9:00 AM

Senzime Advances Sustainable Anesthesia Monitoring with Launch of New EMG Sensor

Senzime

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release5/27/2026, 9:15 AM

From science to practice: Senzime obtains FDA 510(k) clearance for enhanced TetraGraph system

Senzime
Regulatory press release5/19/2026, 3:45 PM

BULLETIN FROM ANNUAL GENERAL MEETING IN SENZIME AB (PUBL)

Senzime
Press release4/29/2026, 12:15 PM

Senzime strengthens U.S. operations with new leadership appointments

Senzime
Press release4/24/2026, 11:30 AM

Senzime’s TetraGraph System Contracted on Three Leading GPO Agreements in the US

Senzime
Regulatory press release4/24/2026, 10:00 AM

Senzime publishes annual and sustainability report for 2025

Senzime
Press release4/23/2026, 7:34 AM

Redeye: Senzime (Q1 Review): Temporary growth dip, with Q2 recovery expected

Senzime
Regulatory press release4/22/2026, 6:00 AM

Margins strengthened and cash flow improved despite a temporary dip in the growth trajectory. Full-year targets remain on track.

Senzime
Press release4/20/2026, 7:00 AM

Senzime wins expanded contract within leading southeastern US hospital system

Senzime
Regulatory press release4/17/2026, 3:30 PM

NOTICE OF ANNUAL GENERAL MEETING IN Senzime AB (publ)

Senzime
Press release4/17/2026, 8:00 AM

Invitation to presentations of Senzime’s first quarter 2026 report

Senzime
Press release4/9/2026, 12:00 PM

Senzime secures strategic hospital orders within leading US integrated healthcare delivery network

Senzime
Press release2/19/2026, 8:35 AM

Redeye: Senzime (Q4 Review): Solid report and a positive 2026 outlook

Senzime
Press release2/19/2026, 8:00 AM

Senzime launches TetraCom connectivity platform enabling universal transmission of anesthesia data

Senzime
Press release2/18/2026, 10:30 AM

Redeye: Senzime (Q4 Initial take): Sales spot on to our estimate

Senzime
Regulatory press release2/18/2026, 7:30 AM

Senzime Q4 2025: Accelerated growth and continued clear path to profitability

Senzime
Regulatory press release2/18/2026, 7:30 AM

Senzime secures credit line facility of 50 MSEK

Senzime
Press release2/11/2026, 12:45 PM

Invitation to presentations of Senzime’s Q4 and Year-End Report 2025

Senzime